Intercell AG

EANS-Adhoc: Intercell AG appoints Staph Leavenworth Bakali as Chief Business Officer - Management Board addition with a successful proven track record in vaccines industry

@@start.t1@@--------------------------------------------------------------------------------   ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide   distribution. The issuer is solely responsible for the content of this   announcement. --------------------------------------------------------------------------------@@end@@

30.09.2010

Vienna (Austria), September 30, 2010 - Intercell AG (VSE: ICLL) today announced that effective October 1, 2010, Staph Leavenworth Bakali will join its Management Board as Chief Business Officer with key responsibilities for the commercial aspects of the Company, directly leading Marketing and Sales, Corporate and Business Development, and Alliance Management. Staph will also play a key role with the other Management Board members in helping drive forward the Company's strategy. Prior to the appointment to Intercell AG's Management Board, Staph had stepped down from his position as member of the Supervisory Board of the Company.

"Staph has an outstanding track record in the vaccines industry and has made major contributions to the success of some key vaccines businesses globally. His commercial and strategic experience ideally complement the skills of our current Management Board", said Gerd Zettlmeissl, Chief Executive Officer of Intercell AG. "We are proud to have Staph working with us towards the next growth phase of our Company."

"Having been a member of Intercell's Supervisory Board for almost five years, I have been impressed with the progress and capabilities of the Company and its people in creating value through innovation, industrialization and commercialization", said Staph Bakali. "I am delighted to join a very dynamic team and look forward to helping develop the business further."

Staph brings 20 years of vaccine industry experience from his previous leadership positions. He was recently Chief Executive Officer of Genocea Biosciences, a Boston (U.S.) based innovative biotech vaccine company, and previously Chief Operating Officer for ID Biomedical (Vancouver, Canada) and PowderJect (Oxford, UK), which were acquired by GlaxoSmithKline and Chiron, respectively. Staph Bakali was also previously head of Sales and Marketing for Chiron's global vaccine business and SmithKline Beecham's Vaccine Business Unit in France. Staph holds a Masters degree in Management from the London Business School.

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Index:    ATX Prime, ATX
Börsen:  Wien / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: